Global Pompe Disease Treatment Market Research Report Forecast to 2025
|発行||Market Research Future||商品コード||916689|
|出版日||ページ情報||英文 78 Pages
|世界のポンペ病治療市場：2025年までの予測 Global Pompe Disease Treatment Market Research Report Forecast to 2025|
|出版日: 2019年10月31日||ページ情報: 英文 78 Pages||
Pompe Disease Treatment Market Research Report - Global Forecast till 2025
Global Pompe Disease Treatment Market: Information by Type (Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease, Non-Classic Infantile-Onset Pompe Disease), by Therapy (Enzyme Replacement Therapy (ERT) and Gene Therapy), End User (Hospitals & Clinics and Research & Academic Institutes) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025
Pompe disease is a genetic metabolic disorder that is usually seen in infants. This disease is caused due to the mutations in the GAA gene which produces the acid, alpha-glucosidase enzyme, that translates glycogen into a simple form. The absence or mutation in the GAA gene results in the accumulation of glycogen that creates heart problems, muscle weakness, and liver harm that can lead to early death in newborns. Factors such as limited awareness about treatment methods and the high cost of therapy hinder market growth. The key factors that drive the Pompe disease treatment market are increasing government initiatives and increasing R&D by manufacturers. The Global Pompe Disease Treatment Market is likely to register a CAGR of 2.6% to attain USD 1,414.1 Million by the year 2025. The Orphan Products Grants funded 18 new grants from a total of 92 grant applications in 2015, to support around 67 ongoing clinical studies that are related to rare diseases as the government has been taking continuous initiatives for the progress and manufacture of advanced products for the diagnosis and treatment of rare diseases such as Pompe disease. Additionally, the governments of various countries such as Sweden, India, the Netherlands, and South Korea are focusing on approving guidelines for the reimbursement of patients enduring enzyme replacement therapy (ERT) for the treatment of Pompe disease. The State Government of Karnataka along with the Employee State Insurance Corporation provides free of cost ERT to patients with lysosomal storage disorders. Additionally, the Union Ministry of Health and Family Welfare has been taking active initiatives for producing a fund of an amount of 13,940 USD million for the treatment of rare diseases, including lysosomal storage disorders. These growing government initiatives for promoting and advancing Pompe disease treatment solutions are widely expected to spur growth of the global Pompe disease treatment market.
Global Pompe Disease Treatment Market has been segmented on the different basis. Based on Type the market has been segmented into Late-Onset Pompe Disease, Classic Infantile-Onset Pompe Disease and Non-Classic Infantile-Onset Pompe Disease. Based on Therapy, the Global Pompe Disease Treatment Market has been segmented into Enzyme Replacement Therapy (ERT) and Gene Therapy. Based on End User the market has been segmented into hospitals & Clinics and Research & Academic Institutes. Based on region the market has been segmented into different regions like Americas covering North America ( US and Canada) and South America, Europe covering Germany, UK, France, Spain, Italy and Rest of Europe, Asia-Pacific covering China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific, Middle East & Africa. The acid alpha-glucosidase is responsible for breaking glycogen, a complex form of sugar, into its simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and damages the cells and Pompe disease is a infrequent genetic condition, caused due to the mutation in the GAA gene, which is responsible for making an enzyme called acid alpha-glucosidase. tissues. There are three chief segmentation of Pompe disease, each differing based on age and severity. These different segments are late-onset Pompe disease, non-classic infantile-onset Pompe disease, and classic infantile-onset Pompe disease. The treatment of Pompe disease is disease-specific and depends on the symptoms of the disease. The global Pompe disease treatment market on the basis of therapy has been divided into, enzyme replacement therapy (ERT), gene therapy, and others. The enzyme replacement therapy (ERT) segment captures the maximum share of the total market as it is the only Food and Drug Administration (FDA) approved therapy for the treatment of Pompe diseases. The Pompe disease treatment market has been fragmented, on the basis of end user, into hospitals & clinics and research & academic institutes. The hospitals & clinics segment was valued at USD 860.8 million in the year 2018, and the research & academic institutes segment accounted for a value of USD 320.7 million in 2018 and are expected to exhibit a CAGR of 2.3% during the forecast period.
Geographically, the global Pompe disease treatment market, based on region, has been split into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is responsible for the major share in the global Pompe disease treatment market owing to the grow in the number of patients with Pompe disease. As per the National Organization for Rare Disorders, the anticipated frequency of the occurrence Pompe disease is approximately 1 in 40,000 in the US. European Pompe disease treatment market is second largest market followed by Asia-Pacific. Europe responsible for the second-major market share in the Pompe disease treatment market owing to factors such as the growing research and development initiatives, support by government for the healthcare sector, and development in settlement policies have improved the market growth. Asia-Pacific is expected to be the fastest-growing region in the global Pompe disease treatment market during the forecast period. increasing healthcare expenditures, growing awareness among patients regarding rare disorders, and improved healthcare are factors which is affecting the the growth of the market. Due to low per capita income and absence of suitable healthcare infrastructure support, the Middle East & Africa responsible for a comparatively lesser market share in the year 2018
The proposed spectators in global Pompe disease treatment market are hospitals, medical devices companies, Research and academic institutes, software companies Governments, associations, industrial bodies, etc. The major companies functioning in the global Pompe disease treatment market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers of the global Pompe disease treatment market are Market research and consulting service providers, Medical research laboratories and Academic medical institutes and universities, Drug Suppliers, Research and development (R&D) companies, Government research laboratories, Independent research laboratories, Government and independent regulatory authorities. Oxyrane, Valerion Therapeutics, AVROBIO, Inc., and CENTOGENE AG., Amicus Therapeutics, Inc., Genzyme Corporation, Audentes Therapeutics are some of major players in the global Pompe disease treatment market. The players operating in the global Pompe disease treatment market is focusing on product launches, along with expanding their global footprints by entering untapped markets.